Logo

Cynvenio Biosystems ClearID HER2 Expression Test

Aug 24, 2017

Cynvenio Biosystems launched its ClearID HER2 Expression Test. The liquid biopsy test allows doctors to perform real-time monitoring and analysis of HER2 levels in patients with a normal blood draw. It leverages Cynvenio's liquid biopsy technology and uses antibodies against EpCAM, TROP2, HER2, and EGFR. The test has a turnaround time of three to seven days and is processed by Cynvenio's CLIA/CAP laboratory in California.

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.